Literature DB >> 16603872

Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.

Jean-Marie Poirier, Jean-Baptiste Guiard-Schmid, Jean-Luc Meynard, Philippe Bonnard, Ouahiba Zouai, Tuna Lukiana, Patrice Jaillon, Pierre-Marie Girard, Gilles Pialoux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16603872     DOI： 10.1097/01.aids.0000222092.97776.cd

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Authors:  Jason J Schafer; Saranyu Ravi; Evelyn V Rowland; Germin Shenoda; Nicholas Leon
Journal:  P T       Date:  2011-06

Review 2.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

Review 3.  Atazanavir: a review of its use in the management of HIV-1 infection.

Authors:  Katherine F Croom; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

4.  Factors influencing lopinavir and atazanavir plasma concentration.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

Review 5.  Efavirenz: a decade of clinical experience in the treatment of HIV.

Authors:  Franco Maggiolo
Journal:  J Antimicrob Chemother       Date:  2009-09-18       Impact factor: 5.790
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.